الفهرس | يوجد فقط 14 صفحة متاحة للعرض العام |
المستخلص Bronchial asthma has become a major public health in the world. It affects more than 334 million people worldwide. The present study was designed to evaluate the potential role of bradykinin antagonists (R - 715; B1 receptor antagonist and Icatibant; B2 receptor antagonist) and cannabinoid agonists [Arachidonyl - 2’ - chloroethylamide (ACEA); CB1 receptor agonist and JWH - 133; CB2 receptor agonist] in treatment of allergic airway inflammation in comparison to dexamethasone and montelukast. Sixty male guinea pigs were allocated into five groups; group (1): Non - sensitized non- treated, group (2): Include OVA - sensitized non-treated guinea pigs that were subdivided into the following subgroups: group (2a): OVA - sensitized saline - challenged non - treated, group (2b): OVA - sensitized OVA - challenged non - treated. group (3): Sensitized OVA - challenged vehicle - treated group. group (4): which was further divided into the following subgroups: group (4a): OVA -sensitized OVA - challenged R - 715 - treated group. group (4b): OVA - sensitized OVA - challenged icatibant - treated: group (4c): OVA-sensitized OVA - challenged ACEA - treated. group (4d): OVA - sensitized OVA - challenged JWH - 133 treated |